alexa Nanocolloids For Cancer
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Nanotek & Expo
December 01-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Mark Kester
ScientificTracks Abstracts: J Nanomed Nanotechnol
DOI: 10.4172/2157-7439.S1.017
Published work by our team has demonstrated that calcium phosphosilicate nanoparticles (CPSNPs) are nontoxic candidates for bioimaging and therapeutic drug delivery applications. The pH-dependent solubility profiles of CPSNPs make this class of nanoparticles especially useful for in vitro and in vivo delivery of fluoroprobes as well as chemotherapeutics. CPSNPs that encapsulate the near infra-red fluoroprobe, indocyanine green, have both diagnostic imaging and therapeutic efficacy. These ?theranostic? attributes can be exploited to enhance photodynamic therapy (PDT), an alternative modality for cancer treatment. ICG-CPSNPs have enhanced optical imaging properties andfunction as stable photosensitizers for PDT. Data will be presented to demonstrate the theranostic potential of ICG-CPSNPs in multiple models of solid and non-solid tumors. In addition to fluoroprobes and chemotherapeutics, CPSNPs can be formulated to encapsulate molecular-based therapies, such as siRNA. Data will also be presented demonstrating the utility of these non-cationic formulations in in vivo models of cancer.
Mark Kester is a Professor of Pharmacology and the Co-Director of the NanoSTAR Institute of the University of Virginia. He was previously the G. Thomas Passananti Professor of Pharmacology at Penn State Hershey College of Medicine and the inagural Director of the Penn State Center for NanoMedicine and Materials. His research interests include the design, characterization and validation of nanotechnologies for targeted drug delivery. His laboratory has evaluated nanoliposomes, nanodendrimers and nanocolloids as effective drug delivery vehicles for pharmacological and molecular agents. Recent work focuses on nontoxic nanoscale systemic delivery systems for hydrophobic pro-apoptotic lipids as well as siRNAs that target mutated tumorigenic proteins. He has consulted with, or founded, several companies that have the license to his nano?Solutions?. In addition, he is a co-author of Integrated Pharmacology, published by Elsevier, Ltd., which was recognized as a ?highly commended textbook? by the British Medical Society.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version